FoRx Therapeutics

Developing portfolio of next-generation DNA damage repair therapeutics focused on DNA replication stress

FoRx Therapeutics is a biotechnology company developing a new generation of first-in-class oral small molecule cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and EQT LS.